• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Arrowhead Pharma (NQ: ARWR )

    27.62 -0.40 (-1.43%)
    Streaming Delayed Price Updated: 3:54 PM EDT, Jul 18, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 732,320
    Open 28.02
    Bid (Size) 27.60 (5)
    Ask (Size) 27.64 (9)
    Prev. Close 28.02
    Today's Range 27.22 - 28.99
    52wk Range 20.67 - 39.83
    Shares Outstanding 105,736,200
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    S&P Global To Rally More Than 13%? Here Are 10 Top Analyst Forecasts For Friday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
    A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides. 
    Via Investor's Business Daily

    Performance

    YTD
    -10.93%
    -10.93%
    1 Month
    +10.04%
    +10.04%
    3 Month
    +22.59%
    +22.59%
    6 Month
    -18.91%
    -18.91%
    1 Year
    -21.06%
    -21.06%

    More News

    Read More
    Have 20 Bucks? 7 Low-Priced Stocks That Could Double by 2025
    Via InvestorPlace
    Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Why Arrowhead Pharmaceuticals (ARWR) Stock Is Seeing Blue Skies
    Via Benzinga
    Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More
    Via Benzinga
    Why Is Arrowhead Pharmaceuticals Stock Trading Higher On Monday?
    Via Benzinga
    Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025
    Via InvestorPlace
    Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    ARWR Stock Earnings: Arrowhead Pharma Misses EPS for Q2 2024
    Via InvestorPlace
    Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Amgen Reports Better-Than-Expected Q1 Results, $50M Milestone Payment
    Via Benzinga
    Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Turnstone Biologics Appoints William Waddill to its Board of Directors
    From Turnstone Biologics Corp.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.